These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 9163888

  • 21. Avoidance of vertebral fractures in men with idiopathic osteoporosis by a three year therapy with calcium and low-dose intermittent monofluorophosphate.
    Ringe JD, Dorst A, Kipshoven C, Rovati LC, Setnikar I.
    Osteoporos Int; 1998; 8(1):47-52. PubMed ID: 9692077
    [Abstract] [Full Text] [Related]

  • 22. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
    Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C.
    J Clin Invest; 1988 Oct; 82(4):1268-74. PubMed ID: 3262626
    [Abstract] [Full Text] [Related]

  • 23. Intranasal salmon calcitonin in postmenopausal osteoporosis: effect of different therapeutic regimens on vertebral and peripheral bone density.
    Perrone G, Galoppi P, Valente M, Capri O, D'Ubaldo C, Anelli G, Zichella L.
    Gynecol Obstet Invest; 1992 Oct; 33(3):168-71. PubMed ID: 1612530
    [Abstract] [Full Text] [Related]

  • 24. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 25. Alendronate for the treatment of osteoporosis in men.
    Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A.
    N Engl J Med; 2000 Aug 31; 343(9):604-10. PubMed ID: 10979796
    [Abstract] [Full Text] [Related]

  • 26. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial.
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD.
    J Bone Miner Res; 2000 May 31; 15(5):944-51. PubMed ID: 10804025
    [Abstract] [Full Text] [Related]

  • 27. [Effectiveness of intranasal salmon calcitonin treatment in postmenopausal osteoporosis].
    Kopaliani M.
    Georgian Med News; 2005 Apr 31; (121):38-42. PubMed ID: 15908722
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.
    Luengo M, Pons F, Martinez de Osaba MJ, Picado C.
    Thorax; 1994 Nov 31; 49(11):1099-102. PubMed ID: 7831624
    [Abstract] [Full Text] [Related]

  • 30. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study.
    Hanley DA, Brown JP, Tenenhouse A, Olszynski WP, Ioannidis G, Berger C, Prior JC, Pickard L, Murray TM, Anastassiades T, Kirkland S, Joyce C, Joseph L, Papaioannou A, Jackson SA, Poliquin S, Adachi JD, Canadian Multicentre Osteoporosis Study Research Group.
    J Bone Miner Res; 2003 Apr 31; 18(4):784-90. PubMed ID: 12674340
    [Abstract] [Full Text] [Related]

  • 31. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.
    Floreani A, Zappala F, Fries W, Naccarato R, Plebani M, D'Angelo A, Chiaramonte M.
    J Clin Gastroenterol; 1997 Jun 31; 24(4):239-44. PubMed ID: 9252849
    [Abstract] [Full Text] [Related]

  • 32. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB, Fraher LJ, Ostbye T, Adachi JD, Steer BM.
    J Clin Invest; 1993 Mar 31; 91(3):1138-48. PubMed ID: 8450043
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Salmon calcitonin in osteoporosis. The effect of intranasal application on bone mineral content and fracture frequency in postmenopausal women with manifest osteoporotic changes].
    Overgaard K, Ravn P, Hansen MA, Christiansen C.
    Ugeskr Laeger; 1993 Aug 02; 155(31):2387-91. PubMed ID: 8346588
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.
    Hodsman AB, Steer BM, Fraher LJ, Drost DJ.
    Bone Miner; 1991 Jul 02; 14(1):67-83. PubMed ID: 1868270
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.